X4 Pharmaceuticals, Inc (XFOR) · Oct 29, 2026 · Other events
2028 data path — Full enrollment Q4 2026; 4WARD topline data Q1 2028
X4 Pharmaceuticals’ investor day lays out the mavorixafor earnings-free development story: a defined 4WARD timeline, new 4STEPS design, and a sizable PCN opportunity—but no new clinical results.
X4 is a focused rare-hematology company with approved mavorixafor in WHIM syndrome and is now trying to extend the drug into primary chronic neutropenia through the pivotal 4WARD Phase 3 trial. That operating story was already established before this filing: the company previously disclosed that 4WARD enrollment had been reduced to 126 patients with expected completion by year-end 2026, and that the trial remained the central execution priority.
The filing mainly confirms the development schedule rather than changing it. X4 says full enrollment of the 126-patient 4WARD study is expected by the end of Q4 2026, with topline data expected in Q1 2028 and potential FDA approval in late 2028 or early 2029. 〔0〕 〔1〕 This is useful timing discipline, but not a new clinical de-risking event; the enrollment and data path had already been outlined in the company’s September update, which described topline data as expected in the first half of 2028.
The incremental information is the shape of the follow-on opportunity. X4 introduces 4STEPS, a roughly 25-patient, open-label Phase 2b study designed to test whether mavorixafor can reduce or eliminate G-CSF injections while maintaining neutrophil counts. The concept fits the company’s commercial positioning—an oral alternative to a burdensome injection-based standard of care—but this is still a planned, single-arm study, not evidence that the strategy works.
The commercial case is more developed, but remains management-generated. The presentation frames an initial U.S. symptomatic population of roughly 15,000 patients with ANC below 1,000 cells/µL and at least two infections, alongside a broader roughly 30,000-patient group with at least one infection. It also supplies patient-burden and physician-intent research to support demand for an oral therapy. Those data improve the commercial narrative, but they are claims analyses and surveys—not observed prescribing, regulatory approval, or Phase 3 efficacy. 〔2〕 〔3〕
The key unresolved issue is still execution and proof. 4WARD must show both an ANC response and lower annualized infection rates in a small pivotal population; the filing gives study design and statistical-power claims, but no interim efficacy, safety, enrollment-completion, or cash-flow update. The broader investor-day message therefore reinforces X4’s existing plan without materially shortening the risk gap between an attractive mechanism and a successful chronic-neutropenia approval.
Bottom line: This is a clearer roadmap for X4’s mavorixafor expansion, not a clinical milestone. It matters for framing the opportunity and upcoming catalysts, but the business still turns on completing 4WARD and producing convincing data in 2028.
4WARD enrollment completion, expected by end of Q4 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!